A Bayesian Joint Modelling for Misclassified Interval-censoring and
Competing Risks
A Bayesian Joint Modelling for Misclassified Interval-censoring and
Competing Risks
In active surveillance of prostate cancer, cancer progression is interval-censored and the examination to detect progression is subject to misclassification, usually false negatives. Meanwhile, patients may initiate early treatment before progression detection, constituting a competing risk. We developed the Misclassification-Corrected Interval-censored Cause-specific Joint Model (MCICJM) to estimate the association between …